BR0313602A - Método e formulação de complexo de aripiprazol - Google Patents

Método e formulação de complexo de aripiprazol

Info

Publication number
BR0313602A
BR0313602A BR0313602-7A BR0313602A BR0313602A BR 0313602 A BR0313602 A BR 0313602A BR 0313602 A BR0313602 A BR 0313602A BR 0313602 A BR0313602 A BR 0313602A
Authority
BR
Brazil
Prior art keywords
formulation
aripiprazole
irritation
injection site
intramuscular injection
Prior art date
Application number
BR0313602-7A
Other languages
English (en)
Inventor
Manoj Nerurkar
Vijay Naringrekar
Mark Dominick
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31946748&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0313602(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR0313602A publication Critical patent/BR0313602A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"MéTODO E FORMULAçãO DE COMPLEXO DE ARIPIPRAZOL". A presente invenção refere-se a uma formulação de aripiprazol que inclui o agente antipsicótico aripiprazol na forma de um complexo de inclusão em uma beta-ciclodextrina, de preferência, beta-ciclodextrina de éter de sulfobutila (SBECD), que na forma de um injetável produz irritação reversível em geral de mínima a moderada no sítio de injeção intramuscular. Um método para minimizar ou reduzir irritação causada por aripiprazol em um sítio de injeção intramuscular e um método para o tratamento de esquizofrenia que emprega a formulação acima são também providos.
BR0313602-7A 2002-08-20 2003-08-14 Método e formulação de complexo de aripiprazol BR0313602A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40471302P 2002-08-20 2002-08-20
PCT/US2003/025573 WO2004017897A2 (en) 2002-08-20 2003-08-14 Aripiprazole complex formulation and method

Publications (1)

Publication Number Publication Date
BR0313602A true BR0313602A (pt) 2005-06-21

Family

ID=31946748

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0313602-7A BR0313602A (pt) 2002-08-20 2003-08-14 Método e formulação de complexo de aripiprazol

Country Status (32)

Country Link
US (8) US7115587B2 (pt)
EP (1) EP1542668B1 (pt)
JP (1) JP4729306B2 (pt)
KR (1) KR101043866B1 (pt)
CN (1) CN100335047C (pt)
AR (2) AR040887A1 (pt)
AT (1) ATE428423T1 (pt)
AU (1) AU2003269965B2 (pt)
BR (1) BR0313602A (pt)
CA (1) CA2495864C (pt)
CY (1) CY1110331T1 (pt)
DE (1) DE60327225D1 (pt)
DK (1) DK1542668T3 (pt)
ES (1) ES2322953T3 (pt)
GE (1) GEP20063996B (pt)
HR (1) HRP20050149B1 (pt)
IL (1) IL166623A (pt)
IS (1) IS2878B (pt)
MX (1) MXPA05001865A (pt)
MY (1) MY140793A (pt)
NO (1) NO333458B1 (pt)
NZ (1) NZ537995A (pt)
PE (1) PE20040895A1 (pt)
PL (1) PL212428B1 (pt)
PT (1) PT1542668E (pt)
RS (1) RS51903B (pt)
RU (1) RU2342931C2 (pt)
SI (1) SI1542668T1 (pt)
TW (1) TWI307626B (pt)
UA (1) UA79984C2 (pt)
WO (1) WO2004017897A2 (pt)
ZA (1) ZA200501064B (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040170705A1 (en) * 2001-03-08 2004-09-02 Dusan Miljkovic Compositions and methods for non-insulin glucose uptake
WO2004017897A2 (en) 2002-08-20 2004-03-04 Bristol-Myers Squibb Company Aripiprazole complex formulation and method
JP4836797B2 (ja) * 2003-10-23 2011-12-14 大塚製薬株式会社 放出制御性無菌注射アリピプラゾール製剤および方法
EP1613598B1 (en) * 2003-12-16 2011-10-19 Teva Pharmaceutical Industries, Ltd. Methods of preparing aripiprazole crystalline forms
US7714129B2 (en) 2003-12-16 2010-05-11 Teva Pharmaceutical Industries Ltd. Methods of preparing anhydrous aripiprazole form II
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
CA2604281A1 (en) * 2005-04-13 2006-10-26 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising prostaglandin derivatives
AU2006255177A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate imatinib mesylate formulations
JPWO2006134877A1 (ja) * 2005-06-13 2009-01-08 武田薬品工業株式会社 注射剤
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
CA2631233C (en) 2005-11-28 2011-11-08 Marinus Pharmaceuticals Ganaxolone formulations and methods for the making and use thereof
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
CN101322709B (zh) * 2007-06-12 2011-03-02 成都康弘药业集团股份有限公司 一种含有阿立哌唑的药物组合物及其制备方法
PL2170279T3 (pl) * 2007-07-31 2018-05-30 Otsuka Pharmaceutical Co., Ltd. Sposoby wytwarzania zawiesiny arypiprazolu i liofilizowanej formulacji
US8501740B2 (en) * 2007-10-09 2013-08-06 Board Of Regents, The University Of Texas System Methods of treatment of opioid tolerance, physical dependence, pain and addiction with inhibitors of certain growth factor receptors
CA2715422A1 (en) * 2008-03-21 2009-09-24 Elan Pharma International Limited Compositions for site-specific delivery of imatinib and methods of use
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
CA2766088C (en) 2009-06-25 2017-06-13 Alkermes, Inc. Heterocyclic compounds for the treatment of neurological and psychological disorders
CA2766033C (en) 2009-06-25 2016-09-20 Alkermes, Inc. Prodrugs of nh-acidic compounds
WO2011023796A1 (en) 2009-08-31 2011-03-03 Abbott Healthcare Products B.V. Bifeprunox for treating addiction
KR101125210B1 (ko) * 2009-09-11 2012-03-19 주식회사 대웅제약 아리피프라졸-벤토나이트-ａｅａ 혼성체, 이를 함유하는 약학 조성물 및 그 제조방법
US20110140304A1 (en) * 2009-12-10 2011-06-16 Molecular Imprints, Inc. Imprint lithography template
EP2585066B1 (en) 2010-06-24 2018-09-26 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
US8383663B2 (en) * 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
EP4327872A2 (en) 2011-03-18 2024-02-28 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
ES2715562T3 (es) 2011-12-15 2019-06-04 Alkermes Pharma Ireland Ltd Profármacos de compuestos de amina secundaria
TW201332572A (zh) * 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β－環糊精之藥物製劑
ES2774901T3 (es) 2012-02-15 2020-07-23 Cydex Pharmaceuticals Inc Proceso para la fabricación de derivados de ciclodextrina
ES2950418T3 (es) 2012-03-19 2023-10-09 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden alcohol bencílico
ES2764383T3 (es) 2012-03-19 2020-06-03 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden ésteres de glicerol
ES2765036T3 (es) 2012-03-19 2020-06-05 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden esteres de ácidos grasos
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
KR101571670B1 (ko) * 2012-08-08 2015-11-25 주식회사 씨엠지제약 아리피프라졸을 포함하는 경구용 속용 필름 제제
WO2014080285A2 (en) 2012-09-19 2014-05-30 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
GR1008186B (el) 2013-04-22 2014-05-08 "Φαρματεν Α.Β.Ε.Ε.", Φαρμακευτικο σκευασμα περιεχον ενα ατυπο αντιψυχωσικο παραγοντα και μεθοδος για την παρασκευη αυτου
JP6203682B2 (ja) * 2013-07-10 2017-09-27 共和薬品工業株式会社 アリピプラゾール含有水性液剤
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
US20150086408A1 (en) * 2013-09-26 2015-03-26 General Electric Company Method of manufacturing a component and thermal management process
KR20240051283A (ko) 2013-12-24 2024-04-19 버지니아 커먼웰스 유니버시티 산소첨가된 콜레스테롤 술페이트 (ocs) 의 용도
GR1008442B (el) 2014-01-16 2015-03-05 "Φαρματεν Α.Β.Ε.Ε.", Φαρμακευτικο σκευασμα περιεχον αριπιπραζολη ή αλας αυτης
US9452131B2 (en) 2014-03-20 2016-09-27 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
CN105078910B (zh) * 2015-09-22 2018-05-22 成都欣捷高新技术开发有限公司 一种含有依匹哌唑的冻干口服制剂及其制备方法
CA3001722A1 (en) 2015-10-16 2017-04-20 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
CN105616344A (zh) * 2016-01-06 2016-06-01 万全万特制药江苏有限公司 阿立哌唑注射液及其制备方法
EP4101861A1 (en) * 2016-08-02 2022-12-14 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
KR102518846B1 (ko) 2016-08-11 2023-04-05 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
CN110022857A (zh) 2016-11-18 2019-07-16 艾库里斯抗感染治疗有限公司 基于改性环糊精和酸化剂的脒取代β-内酰胺化合物的新制剂、其制备及作为抗微生物药物组合物的用途
WO2019102992A1 (ja) * 2017-11-21 2019-05-31 積水化学工業株式会社 皮膚外用剤
US11273158B2 (en) 2018-03-05 2022-03-15 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
WO2020118142A1 (en) 2018-12-07 2020-06-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of pospartum depression
WO2021026124A1 (en) 2019-08-05 2021-02-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treatment of status epilepticus
MX2022006014A (es) 2019-12-06 2022-06-22 Marinus Pharmaceuticals Inc Ganaxolona para uso en el tratamiento del complejo de esclerosis tuberosa.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
JP2893175B2 (ja) * 1988-10-31 1999-05-17 大塚製薬株式会社 カルボスチリル誘導体
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
IT1263831B (it) * 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
JPH07165616A (ja) * 1993-12-09 1995-06-27 Hisamitsu Pharmaceut Co Inc シクロデキストリンの複合組成物及び複合化法
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
IT1269578B (it) * 1994-04-22 1997-04-08 Chiesi Farma Spa Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
JP4012994B2 (ja) * 1996-05-08 2007-11-28 大塚製薬株式会社 抗不安薬
JPH10194996A (ja) * 1996-12-25 1998-07-28 Janssen Pharmaceut Nv アシル化シクロデキストリン含有製薬組成物
GB9713149D0 (en) * 1997-06-21 1997-08-27 Pfizer Ltd Pharmaceutical formulations
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
CA2311734C (en) 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
SE0200301D0 (sv) 2002-02-01 2002-02-01 Axon Biochemicals Bv Thio-carbostyril derivative
WO2004017897A2 (en) * 2002-08-20 2004-03-04 Bristol-Myers Squibb Company Aripiprazole complex formulation and method
RU2292207C2 (ru) 2002-10-25 2007-01-27 Пфайзер Продактс Инк. Депо-препараты арилгетероциклических активных веществ в виде суспензии

Also Published As

Publication number Publication date
WO2004017897A3 (en) 2004-12-02
US20060234979A1 (en) 2006-10-19
TW200405813A (en) 2004-04-16
AU2003269965B2 (en) 2008-02-21
MY140793A (en) 2010-01-15
US7550445B2 (en) 2009-06-23
TWI307626B (en) 2009-03-21
ATE428423T1 (de) 2009-05-15
DE60327225D1 (de) 2009-05-28
EP1542668A4 (en) 2007-10-17
NO333458B1 (no) 2013-06-10
PL374798A1 (en) 2005-10-31
US20040077594A1 (en) 2004-04-22
JP2006501240A (ja) 2006-01-12
US20110160224A1 (en) 2011-06-30
US7115587B2 (en) 2006-10-03
NO20050661L (no) 2005-03-16
AR102101A2 (es) 2017-02-01
GEP20063996B (en) 2006-12-11
RS20050118A (en) 2007-06-04
HRP20050149A2 (en) 2005-10-31
EP1542668A2 (en) 2005-06-22
EP1542668B1 (en) 2009-04-15
JP4729306B2 (ja) 2011-07-20
AU2003269965A1 (en) 2004-03-11
US20120053145A1 (en) 2012-03-01
UA79984C2 (en) 2007-08-10
HRP20050149B1 (hr) 2014-09-12
CN1674882A (zh) 2005-09-28
IS2878B (is) 2014-04-15
DK1542668T3 (da) 2009-07-20
IS7701A (is) 2005-02-18
MXPA05001865A (es) 2005-06-03
ZA200501064B (en) 2006-12-27
CN100335047C (zh) 2007-09-05
RU2342931C2 (ru) 2009-01-10
PL212428B1 (pl) 2012-09-28
NZ537995A (en) 2007-11-30
US20130045981A1 (en) 2013-02-21
US8999952B2 (en) 2015-04-07
KR101043866B1 (ko) 2011-06-22
RS51903B (sr) 2012-02-29
CY1110331T1 (el) 2015-01-14
US20150328335A1 (en) 2015-11-19
IL166623A (en) 2011-07-31
RU2005107471A (ru) 2005-09-10
US20140235574A1 (en) 2014-08-21
IL166623A0 (en) 2006-01-15
CA2495864C (en) 2011-09-27
WO2004017897A2 (en) 2004-03-04
SI1542668T1 (sl) 2009-08-31
PE20040895A1 (es) 2004-11-20
CA2495864A1 (en) 2004-03-04
AR040887A1 (es) 2005-04-20
ES2322953T3 (es) 2009-07-02
KR20050040927A (ko) 2005-05-03
PT1542668E (pt) 2009-06-09
US20090186903A1 (en) 2009-07-23

Similar Documents

Publication Publication Date Title
BR0313602A (pt) Método e formulação de complexo de aripiprazol
BRPI0717219A2 (pt) "composição imunogênica, método para tratar ou prevenir doença, e, uso de uma composição imunogênica."
BR9914638A (pt) Composto, método para a preparação do mesmo, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio ou doença de um corpo de animal vivo
BR9814923A (pt) Método para tratamento de doença de alzheimer
BRPI0415398A (pt) composto, composição farmacêutica, processo para a preparação da mesma, uso de um composto, método de tratamento de cáncer, e, processo para preparação de um composto
GB0008269D0 (en) Combination chemotherapy
BR0110420A (pt) Agonistas muscarìnicos
BR9806118A (pt) Processos para tratamento de pigmentação de pele
AR041722A1 (es) Formulaciones de liberacion prolongada inyectables
BG64475B1 (bg) Ципразидонови соли
IL216579A (en) History of aminocyclohexyl ether and pharmacy preparations containing them
BR0307875A (pt) Composição que pode ser administrada oralmente para a fotoproteção da pele
UY24543A1 (es) Sal mesilato trihidrato de 5-(2-(4-(1,2-benzoisotiazol- 3-il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona
BR0209129A (pt) Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
WO2005030120A3 (en) Antiangiogenic agents
BR9812362A (pt) Formulação bucodental, utilização de nanofibrilas de celulose, e, processo para espessar uma formulação bucodental
BRPI0517650A (pt) uso de ranolazina em combinação com pelo menos um agente de remodelamento para reversão de remodelamento ventricular esquerdo no tratamento de insuficiência cardìaca
BRPI0713457A2 (pt) composto, uso do mesmo, composição farmacêutica, método de tratamento de arritmias, agente para o tratamento de arritmias, e, processo para preparar um composto
BR0204100A (pt) Composição cosmética, utilização de uma composição cosmética processo de tratamento de cosmético de modelagem permanente ou de alisamento das fibras queratìnicas, e, dispositivo com vários compartimentos
BRPI0406596A (pt) Métodos para tratar a dor articular e melhorar o sono utilizando um agonista/antagonista de estrogênio
BR0315662A (pt) Derivados de 1-(4-benzil-piperazin-1-il)-3-fenil-propenona
WO2002042319A3 (en) 2-substituted estrogens as antiangiogenic agents
WO2008143705A3 (en) Methods and compositions for rapid inactivation of proteins
BRPI0606528A2 (pt) composição para uso no fabrico de medicamentos de tratamento da infertilidade masculina e uso da mesma
EP1178796A4 (en) AMINOIMIDAZOLE CARBOXAMIDE SALTS USEFUL IN THE PREVENTION AND TREATMENT OF LIVER DISEASE

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA.INT.CI. A61K 31/09, A61K 31/496, A61K 31/715, A61K 31/724, A61K 47/12, A61K 47/48, A61K 9/00, A61P 25/18

Ipc: A61K 31/19 (2011.01), A61K 31/715 (2011.01), A61K

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B25A Requested transfer of rights approved

Owner name: OTSUKA PHARMACEUTICAL CO., LTD. (JP)

B15K Others concerning applications: alteration of classification

Ipc: A61K 31/4704 (2006.01), A61K 31/496 (2006.01), A61

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]